Resistència antimicrobiana

Novel Marine Biomolecules against Biofilm (NoMorFilm)

Application to medical devices

01/04/2015 - 31/12/2019
Sara Soto
Horizon 2020 (European Commission)

Over 800,000 prostheses, and an even higher number of catheters, are inserted in patients in the European Union every year. Out of these patients, 7.5% suffer from a post-implant infection. A new surgical intervention to replace the implant is then required with a cost that oscillates between 30,000 and 50,000 euros per patient, depending on the country.

The bacteria and fungi found in infected prostheses do not respond to conventional antibiotics because these pathogens proliferate on the surfaces of the prostheses, or on the inside of the catheters, forming a microbial film called biofilm for which there is no pharmacological treatment. Hence, the search for new effective antibiotics that prevent the formation of biofilm and the resulting replacement of prostheses is of vital importance.

NoMorFilm is a project focused on the search for new biomolecules based on microalgae with antibiotic and antibiofilm activity, which could be incorporated into the prostheses or catheters during the manufacturing process, and thus avoid the complications that can arise after they have been inserted into the patient.

Our Team

Equip ISGlobal

Altres projectes

Veure projectes passats


Combatent la Resistència Bacteriana a Europa


Combatting Bacterial Resistance in Europe - Carbapenem Resistance


Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique


Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals


Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique


Integrating and decentralizing diabetes and hypertension services in Africa


Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.


Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo